Heart valve commissure bridge for valve repair

A shape memory frame device engages heart valve commissures to tension leaflets, addressing regurgitation issues in a minimally invasive manner, enhancing coaptation and supporting further treatments.

DE112022006583T5Pending Publication Date: 2024-12-05ST JUDE MEDICAL CARDILOGY DIV INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE112022006583
Authority / Receiving Office
DE · DE
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-02-03
Filing Date
2022-11-15
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing treatments for heart valve regurgitation, such as surgical heart valves and valve clips, lack minimally invasive options that effectively attenuate regurgitation by improving leaflet coaptation.

Method used

A medical device with a frame made of shape memory material, featuring a central rod and legs with curved sections, is deployed to engage native heart valve commissures, applying outward pressure to tension the leaflets and enhance coaptation, potentially combined with a film element to fill gaps between leaflets.

Benefits of technology

The device minimizes or eliminates regurgitation through improved leaflet coaptation, offering a minimally invasive solution that maintains the native valve's functionality while allowing for additional procedures and compatibility with other treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

A medical device for treating a native heart valve may have a frame made of a shape-memory material, wherein the frame has a central bar extending between a first leg and a second leg of the frame. The frame may transition between a deployed state and an unfolded state. The first leg and the second leg may each have a curved section with a concave outer surface in the unfolded state. The concave outer surface may be dimensioned and shaped to abut a corresponding native commissure of the native heart valve, so that the central bar bridges the native heart valve when the frame is deployed within the native heart valve.
Need to check novelty before this filing date? Find Prior Art

Description

Cross-reference to related applications

[0001] This application claims priority to the filing date of U.S. Provisional Patent Application No. 63 / 306,136, filed February 3, 2022, the disclosure of which is hereby incorporated by reference. Background of the Revelation

[0002] The human heart has four valves that help control the direction of blood flow by allowing antegrade blood flow and preventing retrograde blood flow. These valves include (i) the left atrioventricular valve (also called the mitral valve), (ii) the right atrioventricular valve (also called the tricuspid valve), (iii) the aortic valve, and (iv) the pulmonary valve. The atrioventricular valves separate the corresponding atrium from the corresponding ventricle. The aortic valve separates the left ventricle from the aorta. The pulmonary valve separates the right ventricle from the pulmonary artery.

[0003] Each of these valves consists of one or more leaflets, and each leaflet is connected to an adjacent leaflet at a valve interface. Over time, one or more leaflets and / or the native valve annulus may become diseased or otherwise damaged. For example, the leaflets may calcify and / or become distorted in shape, which can affect the leaflets' ability to close sufficiently (also known as coapting). If the leaflets of a native heart valve cannot close properly, retrograde blood leakage can occur. There are many treatment options to correct the function of a malfunctioning heart valve. For example, surgical heart valves or transcatheter heart valves can be implanted to create an entirely new prosthetic heart valve that takes over the function of the native heart valve.Other treatments have been used specifically for the mitral and tricuspid valves, such as valve clips that clamp the valves together to create a better seal.

[0004] Despite the availability of various treatments to replace or repair the function of a native heart valve, it would be desirable to have additional options, including minimally invasive procedures that effectively mitigate native heart valve regurgitation. Brief summary of Revelation

[0005] According to one aspect of the disclosure, a medical device for treating a native heart valve may include a frame made of a shape memory material, the frame having a central post extending between a first leg and a second leg of the frame. The frame may transition between a deployed state and a deployed state, and the frame may be formed from a solid or hollow tube. The first leg and the second leg may each include a curved portion having a concave outer surface when deployed. The concave outer surface may be sized and shaped to engage a corresponding native commissure of the native heart valve such that the central post bridges the native heart valve when the frame is deployed within the native heart valve.

[0006] According to another embodiment of the disclosure, a method for treating a patient's mitral valve includes loading a medical device into a catheter in a deployed state. The catheter can be advanced through a patient's vasculature to a right atrium of the patient, through an atrial septum, and into a left atrium of the patient while the catheter maintains the medical device in the deployed state. The medical device can be deployed from the catheter into engagement with the mitral valve, wherein the medical device transitions from the deployed state to a deployed state during deployment.When the medical device is in the deployed state, a first limb of the medical device engages a first commissure of the mitral valve, a second limb of the medical device engages a second commissure of the mitral valve, and a central rib extends from the first limb to the second limb such that the medical device presses outwardly on the first commissure and the second commissure. Brief description of the drawings Fig. Figure 1 is a highly schematic cross-sectional view of a human heart showing different delivery methods. Fig. Figure 2 is a very schematic representation of a native mitral valve and the associated cardiac structures. Fig. Figure 3A is a highly schematic representation of a mitral valve treatment device according to an embodiment of the disclosure positioned within a native mitral valve annulus. Fig. 3B is a perspective view of the mitral valve treatment device of Fig. 3A in a relaxed or unfolded state. Fig. 3C is a perspective view of a mitral valve treatment device similar to that shown in Fig. 3A in a collapsed state or in a state of deployment. Fig. 3D is an enlarged view of the dashed circle 3D in Fig. 3B. Fig. 3E is an enlarged view of the dashed circle 3E in Fig. 3C. Fig. 3F is an enlarged view of an alternative embodiment of the Fig. 3E shown recesses and recesses. Fig. 4A is a highly schematic representation of a mitral valve treatment device according to another embodiment of the disclosure positioned within a native mitral valve annulus. Fig. 4B shows a part of the treatment device from Fig. 4A in a ready state. Fig. Figure 5A is a highly schematic representation of a mitral valve treatment device according to another embodiment of the disclosure positioned within a native mitral valve annulus and viewed from the atrial side of the valve. Fig. 5B shows the same device as Fig. 5A, but viewed from the ventricular side of the valve. Fig. Figure 5C is a very schematic sectional view of the treatment device of the Fig. 5A-B, which is inserted into the native mitral valve. Fig. Figure 5D is a very schematic representation of the mitral valve treatment device of Fig. 5A, which is positioned within the native mitral valve annulus with an additional support element. Fig. Figure 5E is a very schematic representation of the mitral valve treatment device of Fig. 5A, which is positioned within the native mitral valve annulus with an alternative additional support element. Fig. 6A is a side view of a heart valve treatment device according to another aspect of the disclosure. Fig. Figure 6B is a very schematic representation of the treatment device of Fig. 6A in a deployed or expanded state within a native mitral valve. Fig. Figure 6C is a perspective view of the treatment device of Fig. 6A in an extended or unfolded state. Fig. Figure 7 shows a schematic representation of the treatment device of Fig. 3A, which is deployed by a catheter with an integrated tensioning mechanism. Fig. 8 is a perspective view of a treatment device for use in three-leaf leaflet valves according to one aspect of the disclosure. Fig. 9 is a highly schematic representation of a treatment device for use in two-leaf leaflet valves according to another aspect of the disclosure. Fig. Figure 10A is a highly schematic representation of a central rod of a treatment device in a first length condition. Fig. 10B shows the central bridge of Fig. 10B in a second length state that is longer than the first length state. Detailed description

[0007] As used herein, the term "proximal" in the context of a valve repair device generally refers to the end of the device closest to the user of the device (e.g., a surgeon or other hospital personnel), while the term "distal" refers to the opposite end. In other words, the front end of the device may be located distal to the back end of the device. As used herein, the terms "substantially," "generally," and "approximately" are intended to indicate that even slight deviations from the absolute value are within the scope of the meaning of the term as so modified. In general, materials described as suitable for components in one embodiment may also be suitable for similar or identical components in other embodiments.

[0008] Fig. 1 is a highly schematic cross-sectional view of the human heart 100. The human heart includes two atria and two chambers: the right atrium 112 and the left atrium 122, and the right ventricle 114 and the left ventricle 124. The heart 100 also includes an aorta 110 and an aortic arch 120. Between the left atrium 122 and the left ventricle 124 is the mitral valve 130. The mitral valve 130, also called the bicuspid valve or left atrioventricular valve, is a bicuspid valve that opens as a result of the increased pressure in the left atrium 122 as it fills with blood. When the atrial pressure rises above the pressure in the left ventricle 124, the mitral valve 130 opens and the blood enters the left ventricle 124. The blood flows through the heart 100 in the direction indicated by the arrows “B”.

[0009] A dashed arrow labeled "TA" indicates a transapical approach for implanting a device, such as a prosthetic heart valve or a device for repairing valves and / or leaflets, in this case, for treating the mitral valve. During transapical delivery, a small incision is made between the ribs and into the apex of the left ventricle 124 to deliver the treatment device to the target site. A second dashed arrow, labeled "TS," indicates a transseptal approach for implanting a treatment device, in which the device is inserted through the septum between the right atrium 112 and the left atrium 122.Typically, the transseptal approach involves advancing a catheter through the femoral vein and then through the inferior vena cava into the left atrium, where a needle or other device pierces the atrial septum to access the mitral valve. However, the transseptal approach can also provide access to the left atrium via the superior vena cava, such as the jugular vein. It is understood that similar approaches can be used to reach the tricuspid valve, although it is understood that piercing the atrial septum would not be necessary if the tricuspid valve is treated via an inferior or superior vena cava approach. Approaches to implanting a heart valve treatment device other than those explicitly described above are also possible.

[0010] Fig. Figure 2 is a more detailed schematic representation of the native mitral valve 130 and its associated structures. As previously mentioned, the mitral valve 130 comprises two valve leaflets, the posterior leaflet 136 and the anterior leaflet 138, located between the left atrium 122 and the left ventricle 124. Cord-like tendons called the chordae tendineae 134 connect the two leaflets 136, 138 to the medial and lateral papillary muscles 132. During atrial systole, blood flows from the higher pressure in the left atrium 122 to the lower pressure in the left ventricle 124. When the left ventricle 124 contracts during ventricular systole, the increased blood pressure in the ventricle compresses the leaflets 136, 138, preventing backflow of blood into the left atrium 122.Because the blood pressure in the left atrium 122 is much lower than that in the left ventricle 124, the valve leaflets 136, 138 attempt to tilt toward the low-pressure areas. The chordae tendineae 134 prevent inversion by contracting, pulling on the valve leaflets 136, 138 and holding them closed. The tricuspid valve is generally similar in shape to the mitral valve, although the mitral valve is usually more complex. The tricuspid valve, as its name suggests, typically has three leaflets, as opposed to the typical two leaflets of the mitral valve.

[0011] Two types of native valve treatments have been described above: prosthetic heart valves, which replace most or all of the functionality of the native valve, and valve clips, which clamp the native valves together to improve the seal between the remaining, unstrapped portions of the native valves. The heart valve treatment devices described here may help reduce or eliminate regurgitation at the native heart valve by pulling apart the natural commissures of the native valve leaflets, which may lead to better coaptation of the valve leaflets and thus reduce or eliminate regurgitation.

[0012] Although the heart valve treatment devices are described below generally in the context of treating the mitral valve, the devices can also be used, with or without modification, to treat other native heart valves, such as the tricuspid valve, aortic valve, or pulmonary valve.

[0013] Fig. Figure 3A is a perspective view of a heart valve treatment device 200 being inserted into the annulus of a native mitral valve 130. It is understood that Fig. Figure 3A is a simplified drawing in which the structures of the native mitral valve 130, such as the leaflets, the chordae tendineae, etc., are not shown - many of which are in Fig. 2. In the view of Fig. 3A is the inflow side (or the atrial side) at the top, while the outflow side (or the ventricular side) is at the bottom. As shown in the Fig. 2-3A, the native mitral valve 130 may be generally "D"-shaped or oval and may have two commissures 131, 133 where the posterior leaflet 136 and the anterior leaflet 138 meet.

[0014] As in the Fig. As shown, the heart valve treatment device 200 may be formed as a tube made of a material with shape memory properties. An exemplary shape memory material is a nickel-titanium alloy, such as nitinol, although it should be understood that other shape memory materials may be suitable in place of (or in addition to) nitinol. The treatment device 200 may include three main parts, including a central rod 210, a first leg 220, and a second leg 230. Generally, in use, the treatment device 200 is inserted into the annulus of the native mitral valve 130 such that the first leg 220 and the second leg 230 lie within the native valve commissures 131, 133, such that the treatment device bridges the commissures 131, 133 and exerts outward pressure on the commissures.This outward force on the native commissures 131, 133 can help tension the native valve leaflets 136, 138, resulting in better coaptation of the native valve leaflets and minimizing or eliminating any regurgitation across the native mitral valve 130. The central web 210 is preferably oriented toward the inflow or atrial side of the native mitral valve 130 when deployed, for example, to avoid interference with the native leaflets 136, 138 extending in the outflow (or ventricular) direction from the annulus of the native mitral valve 130. Although the treatment device 200 is described as being formed from a tube of shape memory material, other configurations may be suitable.For example, in some embodiments, the treatment device 200 may be formed from braided strands of a shape-memory material, including braiding into a generally cylindrical or tubular shape. In other embodiments, the treatment device 200 may have a cross-sectional profile other than circular, including oval, square, rectangular, etc.

[0015] Structurally, the treatment device 200 can be formed as a cylindrical tube (e.g., with a circular cross-section) and then formed into the desired shape (e.g., by heat setting), as shown in the Fig. 3A-B. The adjusted shape of the treatment device 200 may include a generally straight section referred to as the central web 210. Extending from either side of the central rod may be two legs 220, 230, which are preferably mirror images of each other, although in some embodiments, the two legs 220, 230 need not have identical mirrored shapes. The first leg 220 may include a first curved section 222 extending from a first end of the central rod 210 and a second curved section 224 extending from the first curved section 222 and extending to a first terminal end of the treatment device 200.Similarly, the second leg 230 may include a first curved portion 232 extending from a second end of the central rod 210 and a second curved portion 234 extending from the first curved portion 232 and leading to a second terminal end of the treatment device 200.

[0016] The first curved sections 222, 232 may each be curved such that the outer surfaces of the first curved sections are convex and the inner surfaces of the first curved sections are concave, such that the first curved sections have a curvature that generally bends in a direction back toward the central rod 210. The transitions between the first curved sections 222, 232 and their respective second curved sections 232, 234 may be inflection points, for example, such that the second curved sections each bend generally in a direction away from the central rod 210 from the inflection point. Using similar terminology as described in the description of the first curved portions 222, 232, the second curved portions 224, 234 may have an outer surface with a concave curvature and an inner surface with a convex curvature.In the description in this section, it should be understood that "inside" and "outside" are terms that refer to the center of the treatment device 200, as opposed to terms that refer to the inside and outside of the tube that forms the treatment device 200. In other words, in the context of this paragraph, an "inside" surface is one that generally faces toward the center of the treatment device 200, while an "outside" surface is one that generally faces away from the center of the treatment device 200. In the configuration described above, the outer surfaces of the second curved portions 224, 234 form a concave curvature into which the commissures 131, 133 of the native mitral valve 130 can fit.As will be apparent from the following description, the treatment device 200 is preferably shaped such that, when no force is applied to the treatment device 200, the distance between the outer surfaces of the second curved portions 224, 234 is greater than the distance between the commissures 131, 133 of the annulus of the native heart valve 130. When the treatment device 200 is deployed in a heart valve such as the native mitral valve 130, the treatment device 200 "wants" to return to its fixed shape, but cannot do so completely because the commissures 131, 133 are closer together than the limbs 220, 230 would be when the treatment device 200 could fully return to its fixed shape.In other words, when the treatment device 200 is deployed in the native mitral valve 130, the legs 220, 230 (and in particular the outer surfaces of the second curved sections 224, 234) press against the commissures 131, 133, thereby slightly tensioning the native valve leaflets 136, 138 while simultaneously maintaining the position of the treatment device 200 in the native mitral valve 130.

[0017] Although the treatment device 200 is preferably installed in the Fig. 3AB or a similar shape, the treatment device 200 may preferably transition to a collapsed state or a ready state, similar to that shown in Fig. 3C. Although the term “folded state” is used here, it should be understood that when transitioning from the Fig. 3B to the state shown in Fig. 3C (or vice versa) no real folding (or expansion) of the treatment device has to take place. Rather, the treatment device has the Fig. 3C, the catheter effectively has a cylindrical shape, thus having a small profile that allows for insertion into the body within a small diameter catheter. For example, a catheter with an outer diameter between about 10 French (3.33 mm) and 24 French (8 mm) can be used to deliver the treatment device 200 transseptally, with the catheter guiding the treatment device in the direction shown in Fig. 3C until the treatment device 200 is released from the catheter so that the treatment device 200 can return (or attempt to return) to its solid form, similar to the Fig. 3A-B. In other words, the delivery catheter for the treatment device 200 may be smaller than a typical delivery catheter used with known heart valve prostheses or valve / leaflet repair devices, such as valve clips.

[0018] The treatment device 200 can be supplied as a solid or hollow tube and then formed into the desired application shape. In some cases, the treatment device 200 can be laser cut or otherwise modified to maintain or achieve specific shape profiles. Fig. 3D shows an enlarged view of the first curved portion 232 of the second leg 230, with focus on the dashed circle 3D in Fig. 3B. Similarly, Fig. 3E is an enlarged view of the second leg 230, with the focus on the dashed circle 3E in Fig. 3C is located. Fig. 3C and Fig. 3E show the treatment device 200 after it has been laser cut (or otherwise modified) to incorporate segmented recesses in the legs 220, 230 that form the transition between the Fig. 3B and Fig. 3C. However, it goes without saying that the segmented cutouts can also be omitted entirely or applied in other formats to perform similar functions.

[0019] In Fig. 3E, the second leg 230 is shown in the collapsed or deployed state. The first curved portion 232 and the second curved portion may each include recesses or indentations formed by any suitable mechanism, including laser cutting, with the recesses or indentations facing in opposite directions. As should be apparent, in this embodiment, the second leg 230 is configured as a hollow tube. The first curved portion 232 may include a substantially continuous spine 232a running along the length of the second leg 230 between the central web 210 and the transition point (or bend point) to the second curved portion 234. The spine 232a may be a wall of the tube forming the treatment device 200, and the spine 232a may be located on the inner surface of the first curved portion 232 in the deployed state.The second curved portion 234 also includes a spine, but this spine is preferably located on the opposite side (e.g., diametrically opposite the spine 232a) such that the spine of the second curved portion 234, when deployed, is located on the outer surface of the second curved portion 234 and is configured to contact and press against one of the native commissures 131, 133.

[0020] As in Fig. 3E, the spine may include two ribs 232b or thin lateral projections extending generally orthogonal to the spine 232a. The ribs 232b may also form part of the wall of the tube forming the treatment device 200. A relatively large clearance may be formed between adjacent pairs of ribs 232b along the length of the spine 232a. The spine 232a and the ribs 232b are shown and described in connection with the first curved portion 232 because they are Fig. 3E are easiest to see on the first curved section 232. However, it goes without saying that the same components may also be present on the second curved section 234b, but they are not visible in the view of Fig. 3E. The other components of the segmented cutouts are described in connection with the second curved section 234, as they are Fig. 3E in conjunction with the second curved section 234 are most easily visible.

[0021] Each of the ribs of a pair of ribs may merge into a segment 234c disposed generally opposite the spine. Each segment 234c may have two side portions 234d defining a circumferential open space 234e therebetween. The two side portions 234d may converge at a protrusion 234f, with the protrusion 234f generally disposed in or adjacent to the open space 234e of an adjacent segment 234c. However, the protrusion 234f of one segment 234c is preferably not directly connected to an adjacent segment 234c. With this repeating configuration, the protrusions of the segments can fit into the open space provided by the adjacent segments as the spine bends or curves, which may help the treatment device 200 more easily assume the desired curved shape.It is understood that other types of segmentations may also be provided to assist in shaping the curvature of the treatment device 200, such as notches or other shaped cutouts.

[0022] The recesses or depressions may provide additional and / or different functions than those described above. For example, the segments could "lock" during the transition to the deployed shape to maintain the curved sections 222, 224, 232, 234 in their desired shape. For example, contact between the structures of adjacent segments may create frictional forces to prevent the curved sections from changing their shape, e.g., due to typical forces that may occur during normal operation due to the movement of the heart muscle, blood flow, etc. Furthermore, the recesses or depressions may help maintain the shape of the delivery catheter during insertion.For example, if the treatment device 200 is constructed from a solid tube of Nitinol (or other shape-memory material) and is adjusted to the desired curvature shown in the figures, the tendency of the treatment device 200 to assume its adjusted shape may, to some extent, "overwhelm" the catheter attempting to maintain the treatment device 200 in a straight or delivery configuration. Instead of the delivery catheter maintaining the treatment device 200 in a completely straight, deployed state, the treatment device 200 may instead begin to return to the adjusted shape to some extent, causing the delivery catheter to bend. However, the likelihood of this occurring may be reduced or eliminated by incorporating the recesses or indentations described above.The precise shape and positioning of the cutouts or recesses can be fine-tuned to optimize the relationship between the strength of the catheter and the strength of the treatment device 200. In other words, the cutouts or recesses can be designed to maximize the strength of the treatment device 200 when in its deployed form within the native heart valve, while at the same time not being so strong that they cause deformation of the delivery catheter during delivery of the treatment device 200. This fine-tuning can be accomplished, at least in part, by increasing or decreasing the amount of material forming a continuous, rigid wall in the treatment device 200, particularly in areas where the treatment device flexes from the straight delivery configuration during delivery into the patient (e.g., sections 222, 224, 232, 234).Furthermore, the structure forming the recesses or depressions may provide additional surfaces capable of engaging or otherwise contacting the tissue upon deployment, thus serving as anchors. For example, some of the surfaces adjacent to the recesses or depressions may dig into the tissue upon deployment and act as prongs, hooks, or barbs, helping to maintain the treatment device 200 in the desired position relative to the native valve annulus.

[0023] As can be seen from the above, although in Fig. 3E shows a specific configuration of recesses and cutouts, various other configurations may be suitable. Another exemplary configuration is shown in Fig. 3F. In Fig. 3F, a portion of a second leg 230' is shown in the folded or deployed state. A first curved portion (in Fig. 3F not shown) and a second curved portion 234' may each have cutouts or recesses formed by any suitable mechanism, including laser cutting, with the recesses or cutouts in each of the curved portions facing in opposite directions, although in Fig. 3F, only a curved section is shown. As should be clear, in this embodiment, the second leg 230' is designed as a hollow tube. The second curved section 234' may be a substantially continuous spine (in the view of Fig. 3F not visible) extending along the length of the second leg 230' and substantially Fig. 3E. The backbone may include two ribs 234b' or thin lateral projections extending generally orthogonal to the backbone. The ribs 234b' may also form part of the wall of the tube forming the treatment device. Each of the ribs of a pair of ribs may merge into a segment 234c' disposed generally opposite the backbone. Each segment 234c' may include two side portions 234d' circumferentially defining an open space 234e' therebetween. The two side portions 234d' may converge at a projection 234f. Each projection 234f may include two lateral tabs that fit into a pair of shoulders, one shoulder of each pair being formed by a side portion 234d' or each pair of side portions 234d'. The Fig. 3F may generally have similar functionality to that used in conjunction with Fig. 3E. However, the tabs and shoulders can provide additional control of the contour of the treatment device during and after deployment. For example, the tabs and shoulders can help ensure that the second curved portion 234' bends only in the desired directions during deployment.

[0024] In a typical use of the treatment device 200, it may first be shaped as described above. For example, a hollow tube made of Nitinol may first be laser-cut to have the segmented cutouts described above and then heat-treated to a shape similar to that described in Fig. 3A. However, it should be understood that in other embodiments, the tube may be solid; in this case, the segmented cutouts may be omitted. Preferably, a plurality of treatment devices 200 of different sizes are provided, and the physician selects the most suitable treatment device 200 based on the anatomy of the patient's mitral valve. As previously mentioned, the physician may, for example, select a treatment device 200 sized such that the length between the concave outer surfaces of the second curved portions 224, 234 of the legs 220, 230 is greater than the distance between the native commissures 131, 133 to ensure that the legs 220, 230 press against the commissures 131, 133 with an outward force upon deployment of the treatment device 200.Once the treatment device 200 of the desired size has been selected, it can be loaded into a catheter, with the treatment device 200 transitioning to the straight or collapsed state during loading. If the legs 220 and 230 are mirror images of each other, it may not matter whether leg 220 is the leading end of the treatment device 200 or leg 230 is the leading end of the treatment device. Once the treatment device 200 is in the delivery catheter, the delivery catheter can be inserted into the patient's vasculature, e.g., the femoral vein, and advanced to the right atrium. If not already done, a needle can be used to pierce the atrial septum. If the treatment device 200 is hollow, the needle can be passed through the center of the treatment device 200.However, in other embodiments, a needle may first be used to pierce the atrial septum, and a guidewire may be advanced through the atrial septum. The guidewire may then be used as a splint for the delivery catheter containing the treatment device 200. It should be understood that these steps are merely exemplary, and other specific techniques may be used to advance the delivery catheter containing the treatment device 200 into the left atrium.

[0025] Once the delivery device is located within the left atrium, the distal tip of the delivery device can be positioned near or adjacent to one of the native commissures, and the treatment device 200 can be extended from the delivery catheter. In one example, a pusher rod or other device can be advanced within the delivery catheter to push the treatment device 200 out of an open distal end of the delivery catheter. In another embodiment, a distal sheath of the delivery catheter can be retracted proximally, and retraction of the distal sheath exposes the treatment device 200. In either case, the shape memory properties of the treatment device 200 cause the treatment device 200 to begin to assume its predetermined shape as the treatment device leaves the constraints of the delivery catheter.For example, one of the limbs is deployed first, and when the second curved portion of that limb is deployed, it is positioned to contact the corresponding native commissures. As deployment continues, the delivery catheter can be withdrawn and / or maneuvered near the opposite commissure so that, upon deployment of the posterior limb of the treatment device 200, the second curved portion of the limb hooks or fits into the remaining native commissure. After the treatment device 200 is fully deployed, it can be positioned as shown in FIG. Fig. 3A, wherein the two legs 220, 230 of the treatment device 200 stretch the native commissure 131, 133, exert tension on the native valve leaflets 136, 138 and promote the co-optation of the valve leaflets.

[0026] It is understood that the treatment device 200 does not require any special anchoring features beyond the force resulting from the shape memory properties of the treatment device 200. For example, the forces of the blood flowing through the native mitral valve 130 may be small compared to the anchoring force provided by the shape memory properties of the treatment device 200. Furthermore, the concave shape of the second rounded portions of the legs 220, 230 may provide a high degree of stability of the position of the treatment device 200 relative to the native mitral valve 130. However, anchoring features may be provided in other embodiments, particularly those described below, which include additional structures on the treatment device.For example, barbs, prongs, hooks, or other features may be provided on the portions of the legs 220, 230 that contact the commissures. These features may serve to pierce the tissue to ensure stable anchorage or simply to create high friction without piercing the tissue.

[0027] Fig. 4A shows a valve treatment device 300 according to another aspect of the disclosure. The treatment device 300 may be essentially the treatment device 200 described above, with a foil element 350 added to the treatment device 200. The foil element 350 may provide a surface against which the native valve leaflets 136, 138 may press when the native valve leaflets coapt. As described in more detail below, the foil element 350 may help fill gaps that would otherwise exist between the coapted native valve leaflets 136, 138 if the foil element 350 were not present.

[0028] The Fig. The valve treatment device 300 shown in Figure 4A may have a similar or identical frame to the treatment device 200 and will therefore not be described in detail again here. However, it should be understood that the treatment device may have a central web 210, a first leg 220, and a second leg 230, and these components may be structurally similar or identical to those described above in connection with the treatment device 200, including any alternatives described. For example, the frame of the treatment device 300 is preferably formed from a hollow or solid tube of a shape memory material, such as a nickel-titanium alloy, and is heat-formed or otherwise molded into the Fig. 4A. The most important structural difference between treatment devices 200 and 300 is that treatment device 300 includes a film member 350 connected to the frame. Film member 350 may be a single-layer (or possibly multi-layer) film of biocompatible material. Film member 350 may be made, for example, from tissue, such as porcine or bovine tissue, including porcine or bovine pericardial tissue. In other embodiments, film member 350 may be formed from a synthetic material (e.g., a polymeric fabric), such as PET, PTFE, another suitable biocompatible sealing material, and / or combinations thereof. Film member 350 may have a shape that generally follows the contours of the frame when the frame is in the Fig. 4A. For example, the top surface of the film member 350 may generally follow the contours of the central web 210, and the sides of the film member 350 may generally follow the contours of the first leg 220 and the second leg 230. The bottom surface of the film member 350 may be generally straight or have any desired contour.

[0029] When the treatment device 300 is deployed in a native heart valve, such as the native mitral valve 130, the treatment device 300 is held in position in substantially the same manner as described above in connection with the treatment device 200. The treatment device 300 can also press against the native commissures 131, 133 to tension the native leaflets 136, 138 in substantially the same manner as described above in connection with the treatment device 200. In the deployed state within a native valve annulus, the film element 350 preferably extends far enough in the outflow direction of the native valve annulus so that when the native valve leaflets 136, 138 abut each other (in Fig. 4A not shown), pressing the native leaflets 136, 138 against opposite sides of the foil member 350. The presence of the foil material 350 between the native leaflets 136, 138 when the native leaflets are coapted can fill any gap between the native leaflets that would otherwise exist in the absence of the foil material 350. In other words, the treatment device 300 can attenuate regurgitation in the same manner as described above in connection with the treatment device 200, but can alternatively or additionally attenuate regurgitation by having the foil member 350 fill any gaps between the native leaflets 136, 138 when the native leaflets are coapted.To be clear, although it is preferred that treatment device 300 provide tension to the native leaflets in the same manner as described above in connection with treatment device 200, treatment device 300 may alternatively apply less tension to the native leaflets, and its primary mode of regurgitation attenuation may be via film member 350. The film member 350 shown in FIG. Fig. The embodiment shown in Figure 4A may be particularly useful in treating prolapsed or flapped leaflet ends. In some embodiments, the foil element 350 may be sized to extend slightly into the patient's ventricle upon implantation of the treatment device 300 to allow the native leaflets to contract early (e.g., anterior to the mitral plane). The foil element 350 may interrupt the arc of the native leaflets, thus shortening the movement, but may also allow the native leaflet to fold over onto the treatment device 300.

[0030] The film member 350 may be attached to the frame of the treatment device 300 in any suitable manner. For example, the film member 350 may be sewn to the central web 210 and / or the first leg 220 and / or the second leg 230 in any desired pattern. In some embodiments, the frame may include openings, notches, or other features to assist in the sewing process. However, the film member 350 may also be attached to the frame of the treatment device 300 in other ways, such as through biocompatible adhesives, etc. In some embodiments, the film member 350 may be folded over the central web 210, with the free ends of the film member 350 being sewn or otherwise secured together. If the film 350 is fabric, it may be ultrasonically welded to secure it to the treatment device 300.As already mentioned, however, these are only exemplary mounting options. In other embodiments, one or more clamps can be used to attach the film element 350 to the frame of the treatment device 300.

[0031] From a procedural perspective, there may be another difference between the insertion and deployment of treatment device 300 compared to treatment device 200. As described above, during deployment, treatment device 200 may be folded or otherwise forced into a deployed state in which the entire treatment device 200 is positioned along a straight line to minimize the deployment profile of treatment device 200. Although the same process is possible for treatment device 300, the material from which film element 350 is constructed would either need to be stretchable (e.g., if constructed from certain synthetic materials), or the connection of the sides of film element 350 to first leg 220 and second leg 230 would need to allow for relative movement, e.g., via sliding stitches.Otherwise, if the frame of the treatment device 300 were folded into a single, substantially straight line, there would be a risk of the film element 350 tearing or otherwise being damaged by the tension acting on the film element 350. However, this tearing or damage can be avoided by folding the frame of the treatment device 300 for deployment in the manner shown in . Fig. 4B. In other words, in the folded or deployed state, the ends of the frame of the treatment device 300 (e.g., the first curved portion 224 and the second curved portion 234) would fold to face each other instead of away from each other, such that the frame of the treatment device 300 is approximately twice as thick in the folded regions. Although this method would increase the profile of the treatment device 300 for delivery compared to the treatment device 200, the film member 350 (in Fig. 4B not shown) from tearing or other damage during deployment. However, in some embodiments, this stronger profile may be desirable. For example, the reinforced profile may have a more oval shape in cross-section, compared to the circular shape used in conjunction with Fig. 3C. For example, the treatment device 300 may be used with a delivery catheter having a generally oval profile that matches the oval profile of the end portions of the treatment device 300 in the deployed state. The matching oval profile may provide an additional level of steering control, as the treatment device 300 may generally be prevented from rotating relative to the delivery catheter while being received by the delivery catheter due to the matching oval profiles.

[0032] As with treatment device 200, treatment device 300 can be supplied in a variety of different sizes to better fit the heart valve being treated in a particular patient (and to apply the desired tension to the native leaflets of the heart valve). However, treatment device 300 can also be supplied with a variety of different thicknesses of film element 350. For example, if a patient examination shows that there is a 3 mm gap between the native valve leaflets 136, 138, treatment device 300 can be provided with a film element 350 having a thickness of 5 mm to fill the gap. In some embodiments, the thickness of film element 350 can be adjusted to match the native coaptation gap or to be slightly larger (or in some cases even slightly smaller) than a native coaptation gap.The coaptation gap can be determined before treatment using a suitable imaging technique, such as echocardiography.

[0033] In the Fig. 1 shows a valve treatment device 400 according to another aspect of the disclosure. The treatment device 400 may be essentially the treatment device 300 described above, with a modified foil member 450, wherein the foil member 450 comprises two individual foils or flaps 450a, 450b. The foil member 450 may provide a surface against which the native valve leaflets 136, 138 may press when the native valve leaflets coapt, but may also tend to expand or balloon in a retrograde direction upon blood flow (or pressure). By bulging outward when the native leaflets 136, 138 press inward, the foil member 450 may help fill any gaps that would otherwise exist between the coaptated native valves 136, 138 in the absence of the foil member 450.

[0034] As with treatment device 300, treatment device 400 may also have a frame that is similar or identical to treatment device 200, which is why the frame of treatment device 400 is not described in detail here. The transition of treatment device 400 into the collapsed state or the insertion state, as well as the actual method for inserting treatment device 400 into the native heart valve, may be similar or identical to that described in connection with treatment device 300 and is therefore not described in detail here.

[0035] The film element 450 can be made of any of the materials described in connection with the film element 350 and can be attached to the frame in substantially the same manner. The main structural difference between the film element 450 and the film element 350 is that the film element 350 can be made of a single piece, whereas the film element 450 is formed from two separate films or flaps 450a, 450b. However, as with the film element 350, the film element 450 can be a single film folded over the central web 210, whereby the free ends of the film element 450 need not be attached to each other, as may be the case with the film element 350. Each film or flap 450a, 450b can be similar or identical to the film element 350, and the individual flaps 450a, 450b are therefore not described in detail here.The flaps 450a, 450b can be connected to the frame of the treatment device 400 in substantially the same manner as described in connection with the foil element 350. However, it should be understood that the underside of each flap 450a, 450b, which refers to the part farthest from the center bar 210, is not connected to each other. In this configuration, a substantially closed volume is formed between the inner surfaces of the two flaps 450a, 450b, with the only path into this closed volume being through the area defined between the undersides of the two flaps 450a, 450b.

[0036] After implantation of the treatment device 400, the open area between the undersides of the two valves 450a, 450b is oriented in the outflow direction towards the left ventricle, which is shown in the views of Fig. 5A and Fig. 5C generally points downward. When the left atrium 122 contracts, the native valves 136, 138 open and blood flows through the mitral valve into the left ventricle 124. This antegrade blood flow may tend to compress the valves 450a, 450b, and a significant distance remains between the outer surface of the valves 450a, 450b and the native valve annulus, so that the treatment device 400 does not impede blood flow from the left atrium 122 to the left ventricle 124. When the left ventricle 124 contracts to force blood into the aorta, the native leaflets 136, 138 of the mitral valve 130 close (or attempt to close) to prevent blood from flowing in the retrograde direction shown in the view of Fig. 5A and Fig. 5C generally points upwards. Fig. Figure 5B shows the treatment device 400 within the mitral valve 130 from the left ventricle while the left ventricle contracts. The natural valve leaflets 136, 138 are omitted for clarity in the view of Fig. 5B are omitted, but are in Fig. 5C. When the left ventricle 124 contracts and the retrograde blood flow creates pressure to close the native valves 136, 138, the retrograde blood flow flows through the open area between the undersides of the valves 450a, 450b and into the otherwise closed volume between the two valves 450a, 450b. When the retrograde blood flow enters the volume between the valves 450a, 450b, as in Fig. 5B, the valves tend to bulge outward, forming contact surfaces against which the native leaflets 136, 138 can close to improve the seal with the mitral valve 130. Although the treatment devices 400 and 300 may both be helpful in patients with regurgitation at the mitral valve 130, the treatment device 400 may be particularly helpful in patients who have a large gap between the native leaflets 136, 138 when the native valve closes, as the leaflets 450a, 450b may be able to fill more space than the single foil element 350.

[0037] Although the treatment device 400 can remain fixed in position without additional support, it should be understood that the treatment device 400 is likely subjected to greater forces during normal operation compared to the treatment devices 200 and 300. In particular, during left ventricular contraction, retrograde blood flow into the volume between the valves 450a, 450b may be significant and may cause the treatment device 400 to attempt to migrate into the left atrium in the retrograde direction or otherwise shift in the anterior or posterior direction (generally perpendicular to the direction in which the central rod 210 extends). Although the frame of the treatment device 400 alone may provide sufficient support, additional support features may be provided in other embodiments.

[0038] Fig. 5D shows the treatment device 400 inserted into the native mitral valve 130 with an additional support element 260. The Fig. The treatment device 400 shown in Figure 5D is identical to the one shown in Fig. 5A-C, except that the additional support member 260 is provided and that features may be incorporated into the central rod 210 to connect the central rod to the additional support member. The additional support member 260 may be in the form of another rod, e.g., a tube made of a shape memory material, such as a nickel-titanium alloy such as Nitinol. In the embodiment shown in Fig. In the deployed state shown in Figure 5D, the additional support member 260 includes a central post that extends generally perpendicular to the central post 210. In other words, while the central web 210 extends in a medial-lateral direction to contact the native commissures 131, 133, the central web of the additional support member 260 extends in an anterior-posterior direction to provide support against anterior-posterior canting or tipping of the treatment device 400. The end portions of the additional support member 260 may include a first curved portion 262 and a second curved portion 264, wherein the curved portions are generally U-shaped or generally C-shaped, although other shapes may be suitable.In the illustrated embodiment, when the treatment device 400 is deployed within the native mitral valve 130, the first curved portion 262 and the second curved portion 264 curve toward the outflow (toward the left ventricle 124) and then back toward the foil member 450. The additional support member 260, and in particular the first and second curved portions 262, 264, may contact the native valve annulus and / or the tissue on the atrial side of the mitral valve 130 to provide additional positional support to the treatment device 400.

[0039] Like the rest of the frame of the treatment device 400, the additional support element 260 is preferably inserted into the Fig. 5D or a similar shape, e.g., by heat setting. With this configuration, the additional support member 260 can be oriented during insertion into a catheter or other delivery device so that it is substantially completely straight, for example, generally cylindrical, to have a low profile. Although the central web 210 of the frame of the treatment device 400 is generally perpendicular to the additional support member 260 during use, the components can be moved so that the frame of the treatment device 400 and the additional support member 260 both extend along a straight line and are parallel (or nearly parallel) to each other during insertion to form a low profile for insertion.

[0040] There are various ways in which the central rod 210 and the additional support element 260 can be shaped to be movable relative to each other to enable the dispensing of small profiles by forming an opening in the central rod 210, as shown in Fig. 5D, and the additional support element 260 is guided through this central opening to couple the two elements so that they are movable, with a hinge-like movement. Alternatively, the treatment device 400', as shown in Fig. 5E, a central rod 210', and an opening may be formed in the additional support element 260' through which the central rod 210' may be guided. The first and second curved sections 262', 264' may be similar or identical to those used in connection with Fig. 5D. Other coupling mechanisms may be suitable to enable the desired functionality. For example, the central bar 210 (or 210') and the additional support member 260 (or 260') may be sewn or otherwise connected together, and instead of openings, the bars may have recesses that allow the central bar and the additional support member to be nested together. In other embodiments, the central rod 210 (or 210') and the additional support member 260 (or 260') may be provided without a fixed connection in the delivery catheter during insertion. The central rod 210 (or 210') and the additional support member 260 (or 260') may be loosely coupled by a suture or a wire so that the treatment device 400 (or 400') can be inserted first while the additional support member 260 (or 260') remains in the catheter.The connecting seam can act as a rail so that the additional support element 260 (or 260') can be inserted second and then pulled into position (e.g., by pulling on the seam until an engaging feature, such as a recess, connects the additional support element to the central rod).

[0041] Fig. 6A shows a treatment device 500 in a folded or deployed configuration according to another embodiment of the disclosure. The treatment device 500 may be substantially identical to the treatment device 200, except for certain differences described below. Therefore, anything not specifically described in connection with the treatment device 500 should be understood as similar or identical to the corresponding features and use of the treatment device 200. The treatment device 500 may, for example, be formed as a solid or hollow tube made of a shape memory material such as a nickel-titanium alloy such as nitinol. As with the treatment device 200, the treatment device 500 may include a central rod 510, a first leg 220, and a second leg 230.The first leg 220 and the second leg 230 of the treatment device 500 may be similar or identical to the first leg 220 and the second leg 230 of the treatment device 200, including the option of being solid or hollow, and the option of including opposing segmented sections. In any of the embodiments described herein, the ends of the treatment device frame may include a wrap or nub of tissue or other atraumatic structures to prevent inadvertent tissue puncture during deployment or during normal operation of the repair device.

[0042] The main difference between the treatment device 500 and the treatment device 200 lies in the difference between the center bar 210 and the center bar 510. As in Fig. 6A, the central web 510 may be formed from two separate segments 510a, 510b spaced apart by a recess or cavity. The segments 510a, 510b may be continuous and / or integral with the rest of the treatment device 500, including the first leg 220 and the second leg 230. For example, the segments 510a, 510b may be formed by subtractive manufacturing, such as laser cutting or etching, as described in Fig. 6A. Each segment 510a, 510b may be referred to as a strut, and each segment may be a wall of the tube from which the treatment device 500 is formed.

[0043] The treatment device 500 is in Fig. 5A in the folded or deployed state, which may be generally identical to the folded or deployed state of the treatment device 200. In other words, the treatment device 500 may have a substantially straight or cylindrical shape in the deployed state. However, as with the other treatment devices described herein, the treatment device 500 is preferably shaped, e.g., by heat setting, to achieve the Fig. 6B when no forces act.

[0044] Fig. 6B shows the treatment device 500 in a deployed or expanded state within the mitral valve 130. The first leg 220 and the second leg 230 of the treatment device 500 may have substantially the same shape as described above in connection with the treatment device 200 when in the deployed or expanded state. However, instead of the central web 210 extending in a relatively straight medial-lateral direction, the struts 510a, 510b of the central web 510 are shaped to extend away from each other in an arcuate shape. As shown in Fig. 6B, the adjusted shape of the struts 510a, 510b together may form a generally circular shape. However, the arc of the struts 510a, 510b may be larger or smaller than that shown in Fig. 6B shown. In Fig. 6C, for example, the treatment device 500 is shown with struts 510a, 510b, which have a smaller arc than in Fig. 6B.

[0045] The use of a splayed or segmented central ridge 510 that opens to form a recess or space between struts 510a, 510b can have several advantages. For example, although central ridge 210 would not be subjected to significant forces from blood flowing antegrade through mitral valve 130, central ridge 510 could be subjected to even fewer forces from blood flowing antegrade through the mitral valve because the blood would tend to flow through the large central opening rather than against struts 510a, 510b. Another advantage is that the positioning of struts 510a, 510b after implantation easily allows for, and may even assist, further interventional procedures.For example, if an additional valve repair device, such as one of the aforementioned valve clips, needs to be implanted in a patient at some point after the treatment device 500 has been implanted, the treatment device 500 would not serve as an obstruction. First, the struts 510a, 510b are positioned away from the center of the mitral valve 130 so that catheters or later devices that need to be passed through the mitral valve would have space between the struts. Second, the struts 510a, 510b (like the central web 210) are positioned on the atrial side of the mitral valve 130 so that clips used to clip the native leaflets 136, 138 on the ventricular side of the mitral valve are not at risk of being interfered with or contacted by the struts 510a, 510b.If a prosthetic mitral valve (particularly a transcatheter prosthetic mitral valve) were to be implanted into the native mitral valve 130 at some point after the implantation of the treatment device 500, the treatment device would not interfere with the prosthetic mitral valve. First, as mentioned above, the opening between the struts 510a, 510b allows a catheter to be easily passed through, if desired. Second, even if a prosthetic mitral valve extends beyond the mitral valve annulus 130 after implantation, the large opening between the struts 510a, 510b allows for clearance between the outer circumference of the prosthetic mitral valve and the inner diameter of the struts 510a, 510b. Third, the struts 510a, 510b may even provide additional anchoring for the mitral valve prosthesis, particularly in expandable mitral valve prostheses.For example, an expandable prosthetic mitral valve can be deployed such that an outer portion of the prosthetic mitral valve contacts and is supported by the native mitral valve annulus, while another supra-annular portion of the prosthetic mitral valve contacts and is supported by struts 510a, 510b. In other words, struts 510a, 510b can serve as a second anchoring ring for a subsequently implanted mitral valve prosthesis, with the annulus of the native mitral valve serving as the first anchoring ring.

[0046] In any of the embodiments described herein, certain other features may be provided for additional functionality. For example, as noted above, hooks, prongs, or other suitable friction-enhancing or piercing elements may be provided on the legs of the treatment devices to enable better anchoring of the treatment device upon implantation. In some embodiments, fabrics or other materials may be provided on one or both legs of the treatment device to support or enhance tissue ingrowth into the treatment device over time. These materials may be any biocompatible material, including synthetic fabrics such as PTE, PTFE, etc.

[0047] As previously mentioned, a procedure in which one of the treatment devices described above is implanted into a native heart valve annulus may be accompanied by other treatment procedures, and the treatment devices described herein may not interfere with those other treatment procedures. For example, a valve clip, such as the MitraClip or TriClip offered by Abbott Labs, may be implanted before or after the treatment devices described herein in a completely separate medical procedure without interference between the two devices. Under certain circumstances, one of the treatment devices described herein may be implanted in a patient as part of the same medical procedure along with another device, such as a valve clip.

[0048] Fig. 7 illustrates how the treatment device 200 is delivered using a catheter 600, with a tensioning mechanism 650 operatively connected to the treatment device 200 to assist in the placement and / or repositioning of the treatment device 200. For example, a suture or other wire 650 may be threaded through the catheter 600 such that both free ends of the suture 650 extend proximally through the catheter 600 toward the operator, with a distal loop of the suture 650 connected to the treatment device. For example, the suture 650 may be looped around the second curved portions 224, 234 of the first and second legs 220, 230.If the suture 650 is placed under tension, for example, by pulling the free ends proximally, the distal loop shortens and the legs 220, 230 are pulled toward each other, thereby reducing the width between the two second curved portions 224, 234 of the legs. This tensioning mechanism 650 can be used during initial deployment of the treatment device 200 to control the extension of one or both legs 220, 230 and / or to control the placement and positioning of the legs 220, 230 relative to the native commissures. The tensioning mechanism 650 can alternatively or additionally be used to assist in repositioning after initial deployment.For example, if after initial insertion of the treatment device 200 into the mitral valve 130, it is determined that repositioning is desirable, the suture 650 may be pulled to draw the legs 220, 230 toward each other to create clearance for repositioning the treatment device. During controlled delivery of the treatment device 200, the tip of the catheter 600 may be pulled against the central web 210 as the tensioning mechanism 650 (e.g., the sutures) is pulled. With this configuration, after tension is applied, the proximal / distal position of the treatment device 200 should be controllable by simply moving the catheter 600 distally or proximally (e.g., distally toward the ventricle or proximally toward the atrium). Additional connecting elements (e.g., sutures) may be connected to only one of the legs to provide additional tilt control.For example, the seam connected to one leg can be pulled to tilt the device in one direction of rotation, or the seam connected to the other leg can be pulled to tilt the device in the opposite direction of rotation.

[0049] While Fig. While Figure 7 shows a tensioning mechanism 650 in the form of a suture that is wrapped around the treatment device 200, if the treatment device is hollow, the suture (or other wire) may instead be threaded through the interior of the tube forming the treatment device 200. For example, the suture 650 could instead have a central portion near the center of the central web 210, with the two ends of the suture passing through the opposing legs 220, 230 and then proximally through the catheter 600, such that pulling the suture proximally has the same effect as pulling the legs 220, 230 together.

[0050] Regardless of whether the tensioning mechanism is located on the outside or inside the treatment device 200, once the operator is satisfied with the final positioning of the treatment device, a free end of the suture 650 can be pulled proximally until the other end passes distally through the catheter, detaches from the treatment device, and then passes proximally back through the catheter 600 to completely separate the suture 650 from the treatment device 200. Although the tensioning mechanism 650 is described only in connection with the treatment device 200, it can of course be used with any of the treatment devices described herein.

[0051] The treatment devices described above have generally been described in the context of treating a bicuspid valve, such as the native mitral valve 130. However, it should be understood that the concepts described in the context of the treatment devices described above can also be applied to tricuspid valves, such as the tricuspid valve, the aortic valve, or the pulmonary valve. Fig. For example, Figure 8 is a perspective view of a treatment device 700 configured for use in a native three-leaf leaflet valve. Treatment device 700 may have two significant structural differences compared to treatment device 200. First, treatment device 700 has three legs 720, 730, 740 instead of two, with each leg substantially similar or identical to legs 220, 230. Second, while treatment device 200 has a single continuous central web 210, treatment device 700 has three central webs 710a-c that meet in the center and extend at an angle of approximately 120 degrees to the respective three legs 720, 730, 740.As with treatment device 200, each leg 720, 730, 740 of treatment device 700 may include a first curved portion with a convex outer surface and a second curved portion with a concave outer surface, wherein the concave outer surfaces are configured to engage the corresponding three native commissures of the native tri-leaflet valve to be treated. Treatment device 700 may be configured as solid tubular elements or as hollow tubular elements with or without segmented sections similar to those described in connection with treatment device 200. All variations described in connection with treatment device 200 may also apply to treatment device 700. For example, the legs 720, 730, 740 of treatment device 700 may include tissue ingrowth and / or enhanced texturing or anchoring features.The treatment device 700 may be provided with a fabric or textile sheet in a three-valve or three-pocket configuration, with a sheet portion extending from each of the central lands 710a-c and / or along each leg 720, 730, 740, wherein the sheet is configured to easily fill any gaps between the leaflets of the native three-valve heart valve, similar to the treatment device 300. Furthermore, instead of individual film portions extending along each central land 710a-c, a film element may extend along each adjacent pair of central lands 710a-c, thus creating volume between adjacent pairs of film elements, similar to the treatment device 400.Furthermore, each central bar 710a-c may be formed with an opening or as a split bar, with the end of each bar being closed near the associated leg, but the openings of each bar converging in the center where three central bars meet. In this embodiment, the treatment device 700 may change shape upon deployment such that the central bars together form a generally circular, open shape, similar to treatment device 500.

[0052] From a process perspective, one of the main differences between a three-leaflet treatment device, similar to treatment device 700, and a two-leaflet treatment device, similar to treatment devices 200-500, is the size of the device when folded. The two-leaflet treatment devices described above can be folded into a single straight or cylindrical tube (as in treatment devices 200, 500) or can fold only portions of the legs to form a dual-profile section (as in treatment devices 300, 400).The treatment device 700, when folded and loaded into a delivery device in the deployment state, may have any two central rods or webs (and their associated legs) pointing in one direction, while the remaining central rod (and its associated leg) points in the opposite direction, such that approximately half the length of the treatment device 700 is "doubled" in the deployment state. If the treatment device 700 is provided with film elements, portions of the legs 720, 730, 740 may be folded for deployment, similar to that described in connection with FIG. Fig. 4B.

[0053] Fig. 9 shows another treatment device 800 for a valve with two leaflets. Although illustrated in a generally simplified form, the treatment device 800 may be formed from a shape memory material, e.g., a solid, hollow, or braided tube, which may have a circular, oval, or rectangular cross-sectional profile. As with the treatment device 200, the treatment device 800 may include a central rod 810. However, the ends of the central rod 810 may directly merge into two ends 820, 830 that are generally C- or U-shaped in the absence of applied forces. Although the two ends 820, 830 may be rigidly connected to the central rod 810, in other embodiments, the two ends 820, 830 may be separately formed and then connected to the central rod 810.In use, the two ends 820, 830 can be folded together so that the two end portions of each of the two ends 820, 830 point away from the central rod, and then received in a delivery device. During deployment, the first end 820 can be deployed to engage one of the native commissures, and the second end 830 can be deployed to engage the other of the native commissures. In other words, each of the two ends 820, 830 can engage the respective commissures by extending a portion above the ring and a portion below the ring, such that the native commissures fit within the "C" shape of the ends 820, 830. In the embodiment shown in FIG. Fig. In the shape adjustment state shown in Figure 9, the central rod 810 may be generally straight and extend between the tips of the "C" shapes of the two ends 820, 830. In this configuration, the central rod 810 extends substantially in the plane of the native valve annulus when the treatment device 800 is deployed within the native valve annulus. The central rod 810 may provide additional structure against which the native valve leaflets can bear when the native valve leaflets transition to the coapted state.

[0054] The Fig. show a central rod 910 that can be used with suitable treatment devices described above, e.g., with treatment device 200. The central rod 910 is not formed as a single integral element, but consists of several parts that can be moved relative to one another to increase or decrease the length between the opposite ends of the treatment device, for example, to increase or decrease the force exerted on the native valve during deployment. In the illustrated embodiment, the central rod 910 has a first rod portion 910a with a larger diameter than the rod portion 910b, so that the rod portions 910a-b can be telescopically connected to one another. In other words, in a first shorter length state, as in Fig. 10A, there is a first relatively large overlap length L1 between the two rod sections 910a-b. In a second state of greater length, as shown in Fig.10B, there is a second, relatively small overlap length L2 between the two rod sections 910a-b. To actuate the central rod 910, any suitable mechanism can be used to change the effective length of the central rod. For example, sliding mechanisms can be used, such as a ratchet and pawl mechanism that allows one-way sliding of the first rod portion 910a relative to the second rod portion 910b. In other embodiments, rotating mechanisms can be used, e.g., through a threaded connection between the two rod sections 910a, 910b. In other embodiments, the central rod 910 can be three-part in a turnbuckle configuration, with two substantially equal-sized central rod sections connected to a turnbuckle mechanism disposed between the two central rod sections.As will be appreciated from the foregoing, the effective length of the treatment device including the central rod 910 may be adjusted before or preferably after insertion into the native valve ring to adjust the level of force exerted on the native valve ring.

[0055] All of the treatment devices described herein are extremely minimally invasive compared to currently known devices for heart valve repair and prosthetic heart valve replacement. Furthermore, even after implantation of one of the treatment devices described herein, additional procedures are generally still possible at a later date, and in some embodiments, the treatment device can even provide support for these later procedures, such as treatment device 500 with struts 510a, 510b, which can provide additional anchoring points for a later-implanted heart valve prosthesis. Furthermore, some patients are unable to accept treatment devices that extend a significant distance into a heart chamber.For example, in patients with left ventricular cavity obliteration (“LVCO”), the left ventricle contracts so strongly that any external structure within the left ventricle (e.g., a portion of a prosthetic mitral valve extending any distance into the left ventricle) would occlude the left ventricular outflow tract (“LVOT”) during ventricular systole. In these patients, treatment devices that extend any significant distance into the left ventricle may not be viable treatment options. However, the treatment devices described here do not extend any significant distance in the outflow direction beyond the native valve being treated. Therefore, the treatment devices described here can also be used in patients with LVCO.

[0056] According to one aspect of the disclosure, a medical device for treating a heart valve having two valve leaflets comprises: a frame formed from a shape memory material, the frame having a central rod or bar extending between a first leg and a second leg of the frame, the frame being capable of transitioning between a deployed state and an unfolded state, the frame being formed from a solid or hollow tube, wherein the first leg and the second leg each have a curved portion with a concave outer surface in the deployed state, the concave outer surface being sized and shaped to engage a corresponding native commissure of the bileaflet heart valve such that, when the frame is deployed in the bileaflet heart valve, the central rod bridges the bileaflet heart valve; and / or wherein the shape memory material is a nickel-titanium alloy; and / or wherein, in the deployed state, the central rod, the first leg and the second leg are substantially coaxial; and / or wherein the curved portions of the first leg and the second leg are each first curved portions, and the first leg and the second leg each have a second curved portion with a convex outer surface, the second curved portion connecting the first curved portion to the central rod; and / or wherein the first curved portions of the first leg and the second leg each have a first spine and a group of first recesses or cutouts, and the second curved portions of the first leg and the second leg each have a second spine and a group of second recesses or cutouts; and / or wherein the first backbones are each arranged diametrically opposite the corresponding groups of first recesses and the second backbones are each arranged diametrically opposite the corresponding groups of second recesses; and / or wherein the first spine of the first leg is arranged diametrically opposite the second spine of the first leg, and the first spine of the second leg is arranged diametrically opposite the second spine of the second leg; and / or wherein the central bar consists of a first strut and a second strut with an opening therebetween; and / or wherein, in the deployed state, the first strut and the second strut are each arcuate so that a generally circular or elliptical space is formed between the first strut and the second strut; and / or wherein, in the deployed state, the central rod extends along a first longitudinal axis and the first and second legs each extend along longitudinal axes offset from the first longitudinal axis; and / or wherein a single foil element which, in the unfolded state of the frame, is bounded on three sides by the central rod, the first leg and the second leg and is not bounded by the frame on a fourth side; and / or wherein the single film element is a substantially flat piece of fabric; and / or wherein two foil elements are provided, wherein in the unfolded state of the frame each of the two foil elements is bounded on three sides by the central rod, the first leg and the second leg and is not bounded by the frame on a fourth side; and / or wherein a space is defined between the two film elements, the space being accessible via an opening between the fourth sides of the two film elements in the unfolded state of the frame; and / or wherein the frame has an additional support rod, and the additional support rod extends substantially perpendicular to the central rod or the central bar in the unfolded state of the frame; and / or wherein the additional support rod is movably coupled to the central rod such that the additional support rod can rotate towards or away from the central rod between the deployed state and the deployed state; and / or wherein the medical device is part of a heart valve repair system, further comprising a catheter configured to receive the medical device in the deployed state; and a tensioning mechanism configured to be positioned within the catheter and operably coupled to the medical device such that, in the deployed state of the medical device, proximal movement of the tensioning mechanism causes the curved portions of the first leg and the second leg to move closer together; and / or wherein the tensioning mechanism is a wire or a thread; and / or wherein, in the deployed state of the medical device, the wire or thread wraps around the concave outer surfaces of the curved portions of the first leg and the second leg; and / or wherein, in the deployed state of the medical device, the wire or thread passes through a hollow interior of the medical device and exits the medical device through the end pieces of the curved portions of the first leg and the second leg.

[0057] According to another aspect of the disclosure, a method for treating a patient's mitral valve comprises: Loading a medical device into a catheter in the ready state; Advancing the catheter through a vasculature of the patient to a right atrium of the patient, through an atrial septum, and into a left atrium of the patient while the catheter maintains the medical device in the deployed state; and Deploying the medical device from the catheter and into engagement with the mitral valve, wherein the medical device transitions from the deployed state to a deployed state during deployment; wherein, when the medical device is in the deployed state, a first leg of the medical device engages a first commissure of the mitral valve, a second leg of the medical device engages a second commissure of the mitral valve, and a central rod extends from the first leg to the second leg such that the medical device pushes outwardly on the first commissure and the second commissure.

[0058] Although the invention has been described herein with reference to specific embodiments, these embodiments are intended merely to illustrate the principles and applications of the present invention. It is therefore to be understood that numerous changes may be made to the illustrated embodiments and that other arrangements may be devised without departing from the scope of the present invention as defined by the appended claims.

Claims

[1] A medical device for treating a two-valve heart valve, the medical device comprising: a frame formed from a shape memory material, the frame having a central rod extending between a first leg and a second leg of the frame, the frame being capable of transitioning between a deployed state and an unfolded state, wherein the first leg and the second leg each have a curved portion with a concave outer surface in the deployed state, the concave outer surface being sized and shaped to engage a corresponding native commissure of the bivalve heart valve such that when the frame is deployed in the bivalve heart valve, the central rod bridges the bivalve heart valve. [2] The medical device of claim 1, wherein the shape memory material is a nickel-titanium alloy. [3] The medical device of claim 1, wherein in the deployed state, the central rod, the first leg, and the second leg are substantially coaxial. [4] The medical device of claim 3, wherein the curved portions of the first leg and the second leg are each first curved portions, and the first leg and the second leg each have a second curved portion with a convex outer surface, the second curved portion connecting the first curved portion to the central rod. [5] The medical device of claim 4, wherein the first curved portions of the first leg and the second leg each have a first spine and a group of first recesses, and the second curved portions of the first leg and the second leg each have a second spine and a group of second recesses. [6] The medical device of claim 5, wherein the first spines are each arranged diametrically opposite the corresponding groups of first recesses and the second spines are each arranged diametrically opposite the corresponding groups of second recesses. [7] The medical device of claim 6, wherein the first spine of the first leg is disposed diametrically opposite the second spine of the first leg and the first spine of the second leg is disposed diametrically opposite the second spine of the second leg. [8] The medical device of claim 3, wherein the central post is formed by a first strut and a second strut with an opening therebetween. [9] The medical device of claim 8, wherein, in the deployed state, the first strut and the second strut are each curved to form a generally circular or elliptical space between the first strut and the second strut. [10] The medical device of claim 1, wherein the central rod, in the deployed state, extends along a first longitudinal axis and the first and second legs each extend along longitudinal axes offset from the first longitudinal axis. [11] The medical device of claim 10, further comprising a single film element, wherein the single film element is bounded on three sides by the central rod, the first leg and the second leg in the deployed state of the frame, and is not bounded by the frame on a fourth side. [12] The medical device of claim 11, wherein the single film element is a substantially flat piece of fabric. [13] The medical device of claim 10, further comprising two foil elements, wherein in the deployed state of the frame, each of the two foil elements is bounded on three sides by the central rod, the first leg and the second leg and is not bounded by the frame on a fourth side. [14] The medical device of claim 13, wherein a volume is defined between the two film elements, the volume being accessible via a space between the fourth sides of the two film elements in the unfolded state of the frame. [15] The medical device of claim 14, wherein the frame includes an additional support rod, and the additional support rod extends substantially perpendicular to the central rod when the frame is deployed. [16] The medical device of claim 15, wherein the additional support rod is movably coupled to the central rod such that the additional support rod can rotate toward or away from the central rod between the deployed state and the deployed state. [17] A heart valve repair system comprising: the medical device of claim 1; a catheter configured to receive the medical device in the deployed state; and a tensioning mechanism configured to be positioned within the catheter and operably coupled to the medical device such that, in the deployed state of the medical device, proximal movement of the tensioning mechanism causes the curved portions of the first leg and the second leg to move closer together. [18] The heart valve repair system of claim 17, wherein the tensioning mechanism is a wire or a suture. [19] The heart valve repair system of claim 18, wherein the wire or thread wraps around the concave outer surfaces of the curved portions of the first leg and the second leg in the deployed state of the medical device. [20] The heart valve repair system of claim 18, wherein in the deployed state of the medical device, the wire or thread passes through a hollow interior of the medical device and exits the medical device through the end pieces of the curved portions of the first leg and the second leg. [21] A method of treating a patient’s mitral valve, the method comprising: Loading a medical device into a catheter in the ready state; Advancing the catheter through a vasculature of the patient to a right atrium of the patient, through an atrial septum, and into a left atrium of the patient while the catheter maintains the medical device in the deployed state; and Deploying the medical device from the catheter into engagement with the mitral valve, wherein the medical device transitions from the deployed state to a deployed state during deployment; wherein, when the medical device is in the deployed state, a first leg of the medical device engages a first commissure of the mitral valve, a second leg of the medical device engages a second commissure of the mitral valve, and a central rod extends from the first leg to the second leg such that the medical device pushes outwardly on the first commissure and the second commissure.